Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Mirum Pharmaceuticals, Inc. - common stock
(NQ:
MIRM
)
94.29
-1.74 (-1.81%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mirum Pharmaceuticals, Inc. - common stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
8 Analysts Assess Mirum Pharmaceuticals: What You Need To Know
↗
October 16, 2025
Via
Benzinga
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Combines Strong Growth Momentum with Bullish Technical Setup
↗
September 27, 2025
Mirum Pharmaceuticals (MIRM) shows strong growth momentum with accelerating revenue and earnings, combined with a top-rated technical setup suggesting a potential breakout.
Via
Chartmill
This Riot Platforms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
↗
September 24, 2025
Via
Benzinga
Earnings Scheduled For August 6, 2025
↗
August 06, 2025
Via
Benzinga
Earnings Scheduled For May 7, 2025
↗
May 07, 2025
Via
Benzinga
Preview: Mirum Pharmaceuticals's Earnings
↗
May 06, 2025
Via
Benzinga
Demystifying Mirum Pharmaceuticals: Insights From 6 Analyst Reviews
↗
September 12, 2025
Via
Benzinga
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study
September 08, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows High Growth Momentum and Technical Breakout Potential
↗
September 05, 2025
Mirum Pharmaceuticals (MIRM) shows strong growth momentum with 62% revenue growth and a bullish technical breakout pattern, making it a top biotech stock to watch.
Via
Chartmill
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Screens as a High-Growth Momentum Stock Using Minervini Trend Template
↗
August 30, 2025
MIRUM Pharmaceuticals (MIRM) is a high-growth stock exhibiting a strong technical uptrend and robust revenue growth, making it a standout candidate for momentum investors.
Via
Chartmill
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
August 27, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Deep Dive Into Mirum Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
↗
August 08, 2025
Via
Benzinga
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Surpasses Q2 2025 Estimates with Strong Revenue Growth and Raised Guidance
↗
August 06, 2025
Mirum Pharmaceuticals beats Q2 2025 estimates with $127.8M revenue, narrows losses, and raises full-year guidance. Stock surges 8.6% post-earnings.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
August 06, 2025
Via
Benzinga
Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
August 06, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Fits Minervini’s Trend Template with Strong Growth Momentum
↗
August 06, 2025
Mirum Pharmaceuticals (MIRM) fits Mark Minervini's trend-following strategy with strong technicals, revenue growth, and breakout potential. A high-growth momentum stock worth watching.
Via
Chartmill
Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025
July 30, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer
May 19, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
May 14, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 09, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Beyond The Numbers: 4 Analysts Discuss Mirum Pharmaceuticals Stock
↗
May 09, 2025
Via
Benzinga
Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL
May 09, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
May 07, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
April 30, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses
April 28, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish
↗
April 14, 2025
Livmarli tablets will be available in June through Mirum Access Plus pharmacy.
Via
Stocktwits
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
